fda compounding semaglutide warning november 2025 September 2, 2025: U.S. restrictions have stemmed a flood of compounded and tirzepatide – Partnership for Safe Medicines FDA unleashes warning letters to

We're here to help solve challenges in your researchjust ask us

LegitScript certified, HIPAA compliant with a dedicated footer section, clean disciplinary record, licensed prescribers through Your Big Picture Healthcare, and a verifiable US address in Princeton, NJ

and the potential launch or commercialization of any of the Companys product candidates or products and our strategic and product development objectives and goals, and the other factors discussed under the caption Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the Securities and Exchange Commission on November 12, 2025 and in our other filings with the SEC

It is not FDA-approved for these uses